A biological pathway linking inflammation and depression: activation of indoleamine 2,3-dioxygenase.
Level 5 - mechanism / opinion, no new human data
Narrative review of preclinical and clinical mechanisms without systematic review methodology
PubMed 21792309 · doi:10.2147/NDT.S17573
What was done
This narrative review summarizes preclinical and clinical literature evaluating how inflammation promotes depression. The authors focus on the induction of the enzyme indoleamine 2,3-dioxygenase (IDO) by proinflammatory cytokines and examine the tryptophan-kynurenine metabolic pathway, specifically drawing on evidence from chronic hepatitis C patients undergoing interferon-alpha therapy as a clinical model of immune activation.
What was found
The abstract reports no quantitative findings, effect estimates, or statistical data. It qualitatively describes the mechanistic model wherein IDO activation causes both peripheral/central tryptophan depletion and an accumulation of neurotoxic kynurenine metabolites, which together are hypothesized to impair neurotransmission and induce depression.
Why it matters
The paper outlines a biological framework connecting immune activation to depressive pathophysiology, identifying potential therapeutic targets such as IDO inhibition, cytokine modulation, and kynurenine pathway interventions.
Limits
The paper is a narrative overview rather than a systematic review or primary empirical study. The abstract provides no sample sizes, effect magnitudes, search criteria, or systematic assessment of bias for the underlying preclinical and clinical evidence.
Cited by
- supports Interferon-alpha treatment activates indoleamine 2,3-dioxygenase (IDO), shifting tryptophan metabolism away from serotonin and into kynurenine.